CelltiSS

What is ALGRAFT?

CelltiSS is a conditioned media consisting of growth factors that play a pivotal role in the wound healing process. It is best used in applications involving the treatment of chronic wound healing and skin grafting as it aids in the growth of healthy tissue throughout the treatment of patients.

The conditioned media is obtained from a cell culture collected at 80-90% confluency during the mitotic phase of cell replication for maximum production. It is indicated for wound bed preparation in full-thickness skin loss due to burns, trauma, pressure ulcers, or diabetic ulcers.

CELLTISS COMPOSITIONS

Interleukin-6 (IL-6)
​Vascular Endothelial Growth Factor Receptor 1 (VEGFR-1)
​Interleukin-1 Receptor Type 1 (IL1R1)
​TGF-Beta Receptor Type-2 (TGFBR2)
Fibroblast Growth Factor 1 (FGF1)
Interferon Gamma (IFNG)
Fibroblast Growth Factor Receptor 2 (FGFR2)
Granulocytes-Macrophage-Colony-Stimulating Factor Receptor Subunit Alpha (CSF2RA)
Platelet-Derived Growth Factor Receptor Beta (PDGFRB)
​Transforming Growth Factor Beta-1 (TGFB1)
​Tumor Necrosis Factor (TNF)

ADVANTAGES OF USING CELLTISS

Reduces cell transplantation and complications.
Economical and cost-effective.
No biopsy required.
Readily available.
Minimal risk of rejection.

CELLTISS CASE STUDY

Before

Day 0

After

Day 91

The patient above with diabetes had a wound caused by soft tissue injury. At presentation, the wound was one month old. At the start of the application, there were two wounds located at the base of the left toe, approximately 4 cm2 in size, and one at the tip of the fourth toe, approximately 1 cm2 in size. On day 91, both wounds at the base and tip of the left toe had achieved 100% closure.

Before

Day 0

After

Day 71

This case involved a 36-year-old male with a diabetic foot ulcer located on the lateral side of the right foot caused by callus removal. At presentation, the wound was two months old and had a size of 9 cm2. On day 73, the wound had completely closed with a mild callus formation on the lateral side of the right foot.

Publications

1. Maarof, M., Busra, M. F. M., Lokanathan, Y., Idrus, R. B. H., Rajab, N. F., & Chowdhury, S. R. (2019). Safety and efficacy of dermal fibroblast conditioned medium (DFCM) fortified collagen hydrogel as acellular 3D skin patch. Drug delivery and translational research9(1), 144-161.

2. Busra, F. M., Lokanathan, Y., Nadzir, M. M., Saim, A., Idrus, R. B. H., & Chowdhury, S. R. (2017). Attachment, proliferation, and morphological properties of human dermal fibroblasts on ovine tendon collagen scaffolds: a comparative study. The Malaysian journal of medical sciences: MJMS24(2), 33.

3. Shiplu, R. C., Jing, L. S., Muhammad, N. H., Zolkafli, N. A., Zarin, M. A., Alyani, W., … & Mothar, M. (2019). Exploring The Potential of Dermal Fibroblast Conditioned Medium on Skin Wound Healing and Anti-Ageing. Sains Malays48, 637-644.

4. Maarof, M., Chowdhury, S. R., Saim, A., Bt Hj Idrus, R., & Lokanathan, Y. (2020). Concentration Dependent Effect of Human Dermal Fibroblast Conditioned Medium (DFCM) from Three Various Origins on Keratinocytes Wound Healing. International Journal of Molecular Sciences21(8), 2929.

5. Maarof, M., Lokanathan, Y., Ruszymah, I., Saim, A., & Chowdhury, S. R. (2018). Proteomic analysis of human dermal fibroblast conditioned medium (DFCM). The protein journal37(6), 589-607